Boehringer Ingelheim has announced that the Striverdi Respimat olodaterol soft mist inhaler is now available in the United States. The FDA approved Striverdi Respimat for the treatment of COPD in July 2014.
The company said that a savings program will be available, allowing most patients to get the inhaler free for a period of time. The card will provide the prescription at no cost for 3 months for uninsured and government-insured patients or will cover the copay for 12 months for commercially-insured patients.
BI Senior VP, Marketing Kathleen M. Dowd said, “For over a half century, Boehringer Ingelheim has been a leader in discovering and developing new therapies for respiratory diseases. We’re proud to build upon our respiratory heritage by bringing Striverdi Respimat to market as a new COPD maintenance treatment option. Approximately 15 million Americans have been told by a healthcare provider that they have COPD, and we believe Striverdi Respimat will be a welcome option for providers and patients alike.”
Read the BI press release.
